ValuEngine Upgrades Pressure Biosciences (OTCMKTS:PBIO) to Buy

ValuEngine upgraded shares of Pressure Biosciences (OTCMKTS:PBIO) from a hold rating to a buy rating in a report published on Monday, June 3rd, ValuEngine reports.

OTCMKTS PBIO traded up $0.04 on Monday, hitting $2.58. 14,882 shares of the stock were exchanged, compared to its average volume of 11,987. Pressure Biosciences has a fifty-two week low of $1.52 and a fifty-two week high of $4.10. The firm has a market cap of $4.68 million, a P/E ratio of -0.17 and a beta of 1.12. The firm has a 50-day simple moving average of $2.93.

Pressure Biosciences (OTCMKTS:PBIO) last issued its earnings results on Wednesday, May 15th. The company reported ($2.01) earnings per share (EPS) for the quarter. The firm had revenue of $0.51 million for the quarter. On average, analysts predict that Pressure Biosciences will post -1.14 earnings per share for the current fiscal year.

About Pressure Biosciences

Pressure BioSciences, Inc develops pressure cycling technology (PCT) solutions. Its PCT technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, such as cells and tissues from human, animal, plant, and microbial sources.

Featured Story: What is Depreciation?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Pressure Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pressure Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply